TNFSF10 and hepatocellular carcinoma: Once we determined that sorafenib sensitizes hepatocellular carcinoma cell lines to Apo2L/TRAIL in vitro, we wanted to evaluate the effect of combination of sorafenib with Apo2L/TRAIL, mapatumumab or lexatumumab in other solid tumor cell lines.